Managed care
Corazon T Aguilar, MD, PC
Corazon T Aguilar, MD, PC was paid $6.34M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 26% of everything it billed.
33Billing provider infoCORAZON T AGUILAR, MD, PC
AURORA, CO 80012
AURORA, CO 80012
33aNPI1770604662assigned 04/02/2007
33bProvider typeExclusive Provider Organization
28Total paid$6.34M
24GClaims241,183
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Exclusive Provider Organization providers in Colorado
Rank by total paid#3 of 5
Median peer was paid$6.34M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,223 | $873K | |
| 2019 | 39,189 | $982K | |
| 2020 | 35,527 | $829K | |
| 2021 | 38,401 | $920K | |
| 2022 | 36,047 | $947K | |
| 2023 | 36,222 | $1.12M | |
| 2024incomplete | 22,574 | $674K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 17,769 | 15,966 | $1.67M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 15,650 | 14,111 | $1.01M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.3% | 4,962 | 4,808 | $461K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 7.1% | 4,459 | 4,255 | $449K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.1% | 4,158 | 4,040 | $388K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.5% | 3,276 | 3,032 | $285K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 4.4% | 15,359 | 14,808 | $282K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.2% | 5,179 | 5,002 | $203K |
| 92587 | 3.0% | 5,506 | 5,303 | $192K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.8% | 6,698 | 6,490 | $114K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.6% | 1,047 | 1,000 | $102K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.5% | 7,375 | 7,169 | $98K |
71 more codes
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 1.5% | 8,829 | $95K |
| D0145 | Oral evaluation for a patient under three years of age | 1.3% | 2,678 | $81K |
| 90651 | 1.2% | 2,302 | $79K | |
| 94760 | 1.2% | 46,134 | $75K | |
| 96127 | 1.1% | 5,631 | $69K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.1% | 4,504 | $68K |
| D1206 | Topical application of fluoride varnish | 1.0% | 3,839 | $64K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,236 | $48K |
| 80061 | Lipid panel | <1% | 3,304 | $45K |
| 87631 | <1% | 345 | $43K | |
| 83655 | <1% | 2,963 | $39K | |
| 94010 | <1% | 1,210 | $36K | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 1,341 | $35K |
| 99173 | <1% | 3,676 | $29K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,690 | $26K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,231 | $24K |
| 90686 | <1% | 6,130 | $21K | |
| 90734 | <1% | 1,085 | $17K | |
| 90474 | <1% | 1,440 | $16K | |
| 36416 | <1% | 9,452 | $14K | |
| 85018 | <1% | 5,394 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,716 | $13K |
| D0190 | <1% | 738 | $11K | |
| 90619 | <1% | 466 | $11K | |
| 90670 | <1% | 2,131 | $11K | |
| 99381 | <1% | 111 | $11K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 69 | $10K |
| 90715 | <1% | 773 | $9K | |
| 81025 | <1% | 1,180 | $9K | |
| 99000 | <1% | 9,919 | $8K | |
| 81002 | <1% | 2,554 | $8K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 56 | $5K |
| 90710 | <1% | 207 | $4K | |
| 90681 | <1% | 1,549 | $4K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 45 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 119 | $4K |
| 90633 | <1% | 925 | $3K | |
| 90671 | <1% | 295 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 208 | $3K |
| 87807 | <1% | 183 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 141 | $2K |
| 99383 | <1% | 15 | $2K | |
| 90697 | <1% | 420 | $2K | |
| 99384 | <1% | 13 | $2K | |
| 90698 | <1% | 1,000 | $1K | |
| 90649 | <1% | 143 | $997.68 | |
| 99201 | <1% | 29 | $959.88 | |
| 93000 | <1% | 54 | $926.55 | |
| 90696 | <1% | 174 | $915.33 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 26 | $903.05 |
| 90685 | <1% | 792 | $634.84 | |
| 90716 | <1% | 82 | $371.76 | |
| 96160 | <1% | 270 | $263.86 | |
| 90700 | <1% | 69 | $137.44 | |
| 90647 | <1% | 222 | $100.31 | |
| 90707 | <1% | 83 | $93.96 | |
| 90744 | <1% | 469 | $86.88 | |
| A4617 | Mouth piece | <1% | 420 | $67.68 |
| 87110 | <1% | 16 | $64.28 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 20 | $39.90 |
| 90461 | <1% | 49 | $39.00 | |
| 90656 | <1% | 120 | $17.01 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 84 | $11.02 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $0.12 |
| 90723 | 0% | 111 | $0.00 | |
| 90657 | 0% | 92 | $0.00 | |
| 90677 | 0% | 13 | $0.00 | |
| 88142 | 0% | 14 | $0.00 | |
| 90658 | 0% | 105 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 16 | $0.00 |
| 90687 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEICH, VANNEHE (OPERATIONS)